879877-45-9

Upstream product

• 352304-09-7 5-bromo-1-(2,6-difluorobenzyl)uracil 
• 877242-94-9 {2-[3-(2,6-difluoro-benzyl)-5-(2-fluoro-3-methoxy-phenyl)-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethyl}-carbamic acid tert-butyl ester 
• 5188-07-8 sodium thiomethoxide 
• 85118-00-9 2,6-Difluorobenzyl bromide 
• 352304-10-0 {2-[5-bromo-3-(2,6-difluoro-benzyl)-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethyl}-carbamic acid tert-butyl ester 

Downstream Products

• 855230-42-1 3-(2-amino-2-phenyl-ethyl)-1-(2-fluoro-6-methanesulfonyl-benzyl)-5-(2-fluoro-3-methoxy-phenyl)-1H-pyrimidine-2,4-dione 
• 879878-38-3 {2-[3-(2-fluoro-6-methanesulfonyl-benzyl)-5-(2-fluoro-3-methoxy-phenyl)-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

Uracils as potent antagonists of the human gonadotropin-releasing hormone receptor without atropisomers

Uracil derivatives were designed and synthesized to avoid atropisomers observed in the 6-methyluracils as antagonists of the human GnRH receptor. Optimization at the 1- and 5-positions of the uracil resulted in potent compounds such as 24 (Ki = 0.45 nM).